To the Editor:Allogeneic hemopoietic stem cell transplantation(allo-HSCT)represents the only long-term survival treatment choice for patients with myelodysplastic syndromes(MDS)and MDS/myeloproliferative neoplasm(MPN).Unfortunately,post-hemopoietic stem cell transplantation(HSCT)relapse remains a cause of treatment failure and the results of salvage treatments are poor.Developing better conditioning regimens is urgently needed.Previous studies have shown synergistic antileukemic effects between decitabine(DEC)and idarubicin(IDA).[1]In an attempt to design a conditioning strategy with very low toxicity but considerable myelosuppressive activity and potential immune-enhancing effects for patients with high-risk MDS and MDS/MPN,we combined DEC and IDA with busulfan,cyclophosphamide,andudarabine for a modied myeloablative regimen in this prospective,multicenter cohort study(hereafter referred to as the“DEC/IDA study”).
Yigeng Cao;Mingyang Wang;Fuxu Wang;Wenwen Guo;Yueshen Ma;Xiaoyun Li;Yi He;Aiming Pang;Rongli Zhang;Weihua Zhai;Xin Chen;Qiaoling Ma;Jialin Wei;Donglin Yang;Yong Huang;Dan Feng;Jia Liu;Xin Gao;Shupeng Wen;Wen Wang;Tao Wang;Ying Li;Xiaosheng Fang;Yingchun Li;Xiaohan Zhang;Yun Cai;Yongqi Wang;Weijie Cao;Runqing Lu;Sizhou Feng;Rong Guo;Yuewen Fu;Xin Du;Zhuogang Liu;Xin Wang;Ling Wang;Liangming Ma;Chuanfang Liu;Xuejun Zhang;Mingzhe Han;Erlie Jiang;
Department of Hematopoietic Stem Cell Transplantation Center,State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology,Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300000,ChinaDepartment of Hematology,Second Hospital of Hebei Medical University,Hebei Key Laboratory of Hematology,Shijiazhuang,Hebei 050000,ChinaCenter for Information and Resource,State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology,Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300000,ChinaDepartment of Hematology,Qilu Hospital of Shandong University,Jinan,Shandong 250000,ChinaDepartment of Hematology,Shanxi Bethune Hospital,Third Hospital of Shanxi Medical University,Taiyuan,Shanxi 030032,ChinaDepartment of Hematology,Qingdao Central Hospital,University of Health and Rehabilitation Sciences,Qingdao,Shandong 266042,ChinaDepartment of Hematology,Shandong Provincial Hospital,Cheeloo College of Medicine,Shandong University,Jinan,Shandong 250000,China Department of Hematology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan,Shandong 250000,ChinaDepartment of Hematology,Shengjing Hospital of China Medical University,Shenyang,Liaoning 110000,ChinaDepartment of Hematology,Shenzhen Second People’s Hospital,The First Affiliated Hospital of Shenzhen University,Shenzhen University School of Medicine,Shenzhen,Guangdong 518000,ChinaDepartment of Hematology,Henan Cancer Hospital,Cancer Hospital Affiliated Zhengzhou University,Zhengzhou,Henan 450000,ChinaDepartment of Hematology,Department of Hematology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan 450000,China
药学
regimen;myelo;patients;
《Chinese Medical Journal》 2024 (009)
P.1115-1117 / 3
supported by grants from the Tianjin Health Science and Technology Project(No.TJWJ2022MS001);Clinical research project of Tianjin Society of Hematology and Regenerative Medicine(No.2022 TSHRM08004);Key Project of Tianjin Natural Science Foundation(No.20JCZDJC00410);CAMS Innovation Fund for Medical Sciences(No.2021-I2M-1-073);Haihe Laboratory of Cell Ecosystem Innovation Fund(No.22HHXBSS00034);National Natural Science Foundation of China(Nos.82070192,8230012348,and 82170217)
10.1097/CM9.0000000000002963
评论